Autosomal Dominant Polycystic Kidney Disease - Epidemiology Forecast - 2032

This ‘Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Epidemiology Forecast-2032' report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as Autosomal Dominant Polycystic Kidney Disease trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Autosomal Dominant Polycystic Kidney Disease Understanding

Autosomal dominant polycystic kidney disease, also called “adult PKD” is the most common inherited kidney disorder characterized by the growth of cysts in the kidneys, which eventually leads to kidney failure. A monogenetic disorder, Autosomal Dominant Polycystic Kidney Disease is caused by mutations in either the PKD1 gene found on chromosome 16 or the PKD2 gene found on chromosome 4. Mutations in PKD1 are more common and account for about 85% of all Autosomal Dominant Polycystic Kidney Disease cases.

Autosomal Dominant Polycystic Kidney Disease is characterized by bilateral renal cysts, kidney pain, frequent urinary tract infection, hematuria, nephrolithiasis, hypertension, and progressive renal failure due to progressive enlargement of cysts and fibrosis. It is one of the leading causes of renal replacement and end-stage renal disease.

Aside from renal cysts, patients frequently have extra renal diseases, which consist of cysts in the liver, seminal vesicle, pancreas, arachnoid membrane, and connective tissue abnormalities like mitral valve prolapse, intracranial aneurysms, diverticular disease, and abdominal hernia; hypertension and left ventricular hypertrophy, and hypertension and left ventricular hypertrophy. Other cardiovascular abnormalities include aortic and arachnoid aneurysms. Recognition of these extra renal manifestations (ERM) reduces diagnostic uncertainty and majorly influences the treatment administered.

Autosomal Dominant Polycystic Kidney Disease Diagnosis

Ultrasound is the most reliable, inexpensive, and non-invasive way to diagnose PKD. If someone at risk for PKD is older than 40 years and has a normal ultrasound of the kidneys, they probably do not have PKD. Occasionally, a CT scan (computed tomography scan) and MRI (magnetic resonance imaging) may detect smaller cysts that ultrasound cannot find. MRI is mostly used to measure and monitor the volume and growth of kidneys and cysts.

In some situations, genetic testing might also be done. This involves a blood test that checks for abnormal genes that cause the disease. Genetic testing is not recommended for everyone. The test is costly, and it also fails to detect PKD in about 15% of people who have it.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent cases of Autosomal Dominant Polycystic Kidney Disease, Age-specific cases of Autosomal Dominant Polycystic Kidney Disease, and Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease, the scenario of Autosomal Dominant Polycystic Kidney Disease in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Autosomal Dominant Polycystic Kidney Disease Detailed Epidemiology Segmentation

• Total diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the 7MM were found to be approximately 367,042 cases in the year 2021. The diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease are likely to change by 2032 in the forecast period 2022─2032.
• The United States accounted for approximately 142,709 diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the year 2021.
• In 2021, the total reported diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in EU-5 countries were approximately 193,161 cases which are expected to rise by 2032.
• In 2021, the UK accounted for the highest number of Autosomal Dominant Polycystic Kidney Disease diagnosed prevalent cases (67,419), followed by France (61,282) among EU-5 countries. In contrast, Italy accounts for the lowest number of cases of Autosomal Dominant Polycystic Kidney Disease diagnosed prevalent population in EU-5.
• As perthe analysis, in Japan, Autosomal Dominant Polycystic Kidney Disease cases in the age groups < 5, 5-14, 15-24, 25-44, 45-64, and ≥65 years were observed to be approximately 62, 62, 125, 3,429, 19,576, and 7,918, respectively in 2021. The age-specific cases are expected to change by 2032.

Scope of the Report

• The report covers a descriptive overview of Autosomal Dominant Polycystic Kidney Disease, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Autosomal Dominant Polycystic Kidney Disease.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, a total number of total Diagnosed Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease, Age-specific cases of Autosomal Dominant Polycystic Kidney Disease, and Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease.

 

Report Highlights

• 11-Year Forecast of Autosomal Dominant Polycystic Kidney Disease
• The 7MM Coverage
• Total Diagnosed Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease
• Age-specific cases of Autosomal Dominant Polycystic Kidney Disease
• Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease

Key Questions Answered

• What are the disease risk and burdens of Autosomal Dominant Polycystic Kidney Disease?
• What is the historical Autosomal Dominant Polycystic Kidney Disease patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Autosomal Dominant Polycystic Kidney Disease at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population for Autosomal Dominant Polycystic Kidney Disease?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Autosomal Dominant Polycystic Kidney Disease during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Autosomal Dominant Polycystic Kidney Disease report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Autosomal Dominant Polycystic Kidney Disease epidemiology forecast.
• The Autosomal Dominant Polycystic Kidney Disease epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Autosomal Dominant Polycystic Kidney Disease epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

 

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032